Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer, J. Clin. Oncol 28(28):1131-7, 2010
Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy, J. Clin. Oncol 28(28):1138-44, 2010
Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial), Ann. Oncol. 21(21):1442-7, 2010
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer, J. Clin. Oncol. 28(28):3239-47, 2010
Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated, J. Clin. Oncol. 28(28):960-6, 2010
Dr. J Cortés
Dirección profesional:
Passeig Vall d'Hebron 119; Edifici Maternoinfantil Planta 14 , Barcelona , , España , E-mail: jacortes@vhio.net
|